228 related articles for article (PubMed ID: 30033822)
21. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.
Cornely OA; Aversa F; Cook P; Jones B; Michallet M; Shea T; Vallejo C
Eur J Haematol; 2011 Oct; 87(4):289-301. PubMed ID: 21752098
[TBL] [Abstract][Full Text] [Related]
22. Clinical considerations in the early treatment of invasive mould infections and disease.
Mercier T; Maertens J
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i29-i38. PubMed ID: 28355465
[TBL] [Abstract][Full Text] [Related]
23. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
Ping B; Zhu Y; Gao Y; Yue C; Wu B
Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
[TBL] [Abstract][Full Text] [Related]
24. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
Maertens J
Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
[TBL] [Abstract][Full Text] [Related]
25. The burden of Invasive Aspergillosis in patients with haematological malignancy: A meta-analysis and systematic review.
van de Peppel RJ; Visser LG; Dekkers OM; de Boer MGJ
J Infect; 2018 Jun; 76(6):550-562. PubMed ID: 29727605
[TBL] [Abstract][Full Text] [Related]
26. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Blyth CC; Gilroy NM; Guy SD; Chambers ST; Cheong EY; Gottlieb T; McGuinness SL; Thursky KA
Intern Med J; 2014 Dec; 44(12b):1333-49. PubMed ID: 25482744
[TBL] [Abstract][Full Text] [Related]
27. Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit?
Böhme A; Karthaus M; Hoelzer D
Chemotherapy; 1999; 45(3):224-32. PubMed ID: 10224346
[TBL] [Abstract][Full Text] [Related]
28. Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).
Boğa C; Bolaman Z; Çağırgan S; Karadoğan İ; Özcan MA; Özkalemkaş F; Saba R; Sönmez M; Şenol E; Akan H; Akova M
Turk J Haematol; 2015 Jun; 32(2):100-17. PubMed ID: 26316478
[TBL] [Abstract][Full Text] [Related]
29. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Fleming S; Yannakou CK; Haeusler GM; Clark J; Grigg A; Heath CH; Bajel A; van Hal SJ; Chen SC; Milliken ST; Morrissey CO; Tam CS; Szer J; Weinkove R; Slavin MA
Intern Med J; 2014 Dec; 44(12b):1283-97. PubMed ID: 25482741
[TBL] [Abstract][Full Text] [Related]
30. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
31. Antifungal prophylaxis in haematology patients: the role of voriconazole.
Hicheri Y; Cook G; Cordonnier C
Clin Microbiol Infect; 2012 Apr; 18 Suppl 2():1-15. PubMed ID: 22409648
[TBL] [Abstract][Full Text] [Related]
32. Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.
Pechlivanoglou P; De Vries R; Daenen SM; Postma MJ
Pharmacoeconomics; 2011 Sep; 29(9):737-51. PubMed ID: 21657801
[TBL] [Abstract][Full Text] [Related]
33. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.
Douglas AP; Slavin MA
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1165-1177. PubMed ID: 27710140
[TBL] [Abstract][Full Text] [Related]
34. The role of primary antifungal prophylaxis in patients with haematological malignancies.
Pagano L; Caira M
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
[TBL] [Abstract][Full Text] [Related]
35. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
36. Antifungal prophylaxis in liver transplant recipients: one size does not fit all.
Giannella M; Bartoletti M; Morelli M; Cristini F; Tedeschi S; Campoli C; Tumietto F; Bertuzzo V; Ercolani G; Faenza S; Pinna AD; Lewis RE; Viale P
Transpl Infect Dis; 2016 Aug; 18(4):538-44. PubMed ID: 27237076
[TBL] [Abstract][Full Text] [Related]
37. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
Rogers TR; Slavin MA; Donnelly JP
Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
[TBL] [Abstract][Full Text] [Related]
38. [Relevance of liposomal amphotericin B in the treatment of invasive fungal infections in patients with hematologic malignancies].
García-Vidal C; Vázquez L; Jarque I
Rev Iberoam Micol; 2021; 38(2):61-67. PubMed ID: 33994104
[TBL] [Abstract][Full Text] [Related]
39. [Consensus opinion on antifungal prophylaxis in haematologic patients: Results of the PROMIC project].
Vázquez López L; Villaescusa de la Rosa T; de la Cámara R; Espigado I; Grau Cerrato S; Jurado M; Rovira M; Salavert M; Serrano Simonneau D; Solano Vercet C; Ruiz Camps I
Rev Esp Quimioter; 2017 Jun; 30(3):213-223. PubMed ID: 28537063
[TBL] [Abstract][Full Text] [Related]
40. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?
Cherif H; Kalin M; Björkholm M
Eur J Haematol; 2006 Oct; 77(4):288-92. PubMed ID: 16856930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
